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Abstract
Cysteinyl leukotrienes (cys-LTs) are a group of lipid mediators that are potent bronchoconstrictors, powerful inducers of
vascular leakage and potentiators of airway hyperresponsiveness. Cys-LTs play an essential role in asthma and are
synthesized as well as activated in mast cells (MCs). Cys-LTs relay their effects mainly through two known GPCRs, CysLT1R
and CysLT2R. Although protein kinase C (PKC) isoforms are implicated in the regulation of CysLT1R function, neither the role
of PKCs in cys-LT-dependent MC inflammatory signaling nor the involvement of specific isoforms in MC function are known.
Here, we show that PKC inhibition augmented LTD4 and LTE4-induced calcium influx through CysLT1R in MCs. In contrast,
inhibition of PKCs suppressed c-fos expression as well MIP1b generation by cys-LTs. Interestingly, cys-LTs activated both
PKCa and PKCe isoforms in MC. However, knockdown of PKCa augmented cys-LT mediated calcium flux, while knockdown
of PKCe attenuated cys-LT induced c-fos expression and MIP1b generation. Taken together, these results demonstrate for
the first time that cys-LT signaling downstream of CysLT1R in MCs is differentially regulated by two distinct PKCs which
modulate inflammatory signals that have significant pathobiologic implications in allergic reactions and asthma pathology.
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Introduction
Cysteinyl leukotrienes (cys-LTs), comprising LTC4, LTD4 and
LTE4. are potent bronchoconstrictors and mediators of pulmo-
nary inflammation [1,2]. They are derivatives of arachidonic acid
generated by mast cells (MCs), eosinophils, basophils, macrophag-
es, and myeloid dendritic cells [3]. LTC4 and LTD4 are very
short-lived in vivo while LTE4 is stable, being the only cys-LT
detected in biologic fluids and excreted in the urine [4]. Cys-LTs
potentiate airway hyperresponsiveness (AHR) to histamine when
administered by inhalation to human subjects [5]. Bronchoalve-
olar lavage (BAL) fluids collected from allergic human subjects
after endobronchial challenge with allergen contain high levels of
cys-LTs [6], pointing the role of cys-LTs in allergic inflammation.
This role is confirmed by the fact that inhibitors of the type 1 G
protein-coupled receptor (GPCR) for cys-LTs (CysLT1R) [7,8]
and inhibitors of cys-LT synthesis [9] are clinically efficacious for
the treatment of asthma. Cys-LTs are also implicated in adaptive
immunity and fibrosis [10,11,12]. Most of these cys-LT-mediated
effects are thought to be induced through CysLT1R and a second
GPCR, CysLT2R [13,14], although the existence of additional
receptors is likely based on findings in mice lacking both receptors
[15,16,17]. Identification of signaling partners and mechanisms
involved in the regulation of these receptors is crucial to gain
insight into allergic inflammation.
MCs are stem cell factor (SCF)-dependent hematopoietic cells
that are ubiquitously distributed throughout the body [18,19] and
initiate inflammatory responses to allergens and infectious agents.
They play an important role in triggering exacerbations of asthma
through the elaboration of several soluble inflammatory mediators
including cys-LTs, histamine, serine proteases, multiple cytokines
and chemokines. MCs not only generate cys-LTs, but also express
both CysLT1R and CysLT2R [20,21] and respond to LTC4,
LTD4, and LTE4 with a range of functions. We have demon-
strated earlier that stimulation of human cord blood-derived MCs
(hMCs) and/or LAD2 cells with LTD4 potently induces calcium
flux [21,22] and cytokine generation [22,23], each of which
requires CysLT1R based on pharmacologic antagonism by
MK571. hMCs also proliferate in response to LTD4, reflecting
transactivation of c-kit by CysLT1R [24]. The relevance of cys-
LTs to MC function is suggested by the observation that mice
lacking the requisite terminal enzyme needed for cys-LT
generation, leukotriene C4 synthase, show markedly reduced
numbers of MCs in the airway mucosa following sensitization and
challenge to allergen [12]. However, aside from the ability of
LTD4 to transactivate c-kit [24] and for LTE4 to activate PPARc
[22] and induce the formation of large amounts of cytokines by a
pathway involving the P2Y12 receptor [17], little is understood
concerning the signaling mechanisms by which cysteinyl leukotri-
ene receptors modulate the function of MCs.
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Protein kinase C (PKC) refers to a family of phospholipid-
dependent serine/threonine protein kinases that are activated by a
number of extracellular stimuli including growth factors, adhesion,
cytokines and GPCRs [25]. PKCs are involved in signal
transduction associated with cell proliferation, differentiation,
and apoptosis. At least eleven closely related PKC isozymes have
been reported that differ in their structure, biochemical properties,
tissue distribution, subcellular localization, and substrate specific-
ity. They are classified as classical (a, b1, b2,c), novel (d, e, g, h, m),
and atypical (j, l) isozymes depending on their requirement for
the cofactors calcium, diacylglycerol (DAG) and phosphatidylser-
ine (PS) [26,27,28]. PKCs are implicated in the negative
regulation of LTD4-induced calcium signaling [29,30]. Global
pharmacological inhibition of PKCs was shown to inhibit LTD4-
mediated CysLT1R internalization and desensitization resulting in
enhanced phosphoinositide production and calcium flux [31]. This
CysLT1R desensitization is shown to occur mainly through the
phosphorylation of three serine residues (313–316) in the tail
region of CysLT1R by PKCa [31]. In contrast, Thodeti et al.,
demonstrated that PKCe regulates LTD4-induced Ca
2+ signal in
intestinal epithelial cells [32]. Overall, it is not clear what specific
isoforms are activated by cys-LTs in MCs or how they are involved
in regulation of the LTD4-induced Ca
2+ signal as well MC
activation. In the present study, we investigated the specific PKC
isoforms activated in MCs by cys-LTs and the role of each isoform
in regulating cys-LT-induced MC responses. We show that both
LTD4 and LTE4 activate PKCa and PKCe isoforms and that
these isoforms regulate different signals down-stream of CysLT1R.
Specifically, PKCa negatively regulates cys-LT-induced calcium
flux, while PKCe positively regulates CysLT1R-mediated c-fos
expression and MIP1b generation.
Materials and Methods
Reagents
LTD4, LTE4 and MK571 were purchased from Cayman
Chemical. Fura-2 AM was from Molecular Probes, All phospho-
specific antibodies were from Cell Signaling Technology, Total
PKC antibodies were from Santa Cruz Biotechnology. Isoform
specific siRNAs for PKCs were obtained from Dharmacon and
MIP1b Elisa kit was from Endogen.
Cell Culture
The LAD2 MC leukemia line [33] was a kind gift from Dr.
Arnold Kirshenbaum, NIH. These cells were cultured in stempro-
34 (Invitrogen) supplemented with 2 mM L-Glutamine (Invitro-
gen), Pen-strep (100 IU/ml) (Invitrogen) and SCF (endogen)
(100 ng/ml). Cell culture medium was hemidepleted every week
with fresh medium and 100 ng/ml SCF. Primary hMCs were
derived from cord blood mononuclear cells cultured for 6–9 weeks
in RPMI supplemented with SCF, interleukin IL-6, and IL-10
[34].
Calcium Flux
LAD2 cells or hMCs (0.5–16106/sample) were washed and
labeled with fura 2-AM for 30 minutes at 37uC. Cells were
stimulated with the indicated concentrations of LTD4 and LTE4
and the changes in intracellular calcium were measured using
excitation at 340 and 380 nm in a fluorescence spectrophotometer
(Hitachi F-4500) as described earlier [22]. The relative ratios of
fluorescence emitted at 510 nm were recorded and displayed as a
reflection of intracellular calcium concentration. In some exper-
iments, cells were pre-incubated with the PKC inhibitor
GF109203X (GFX; 2 mM) for 30 minutes or with CysLT1R
antagonist MK571 (1 mM) for 15 minutes before the stimulation
with cys-LTs (500 nM).
Cell Activation
LAD2 cells were either stimulated with 500 nM of LTD4 or
LTE4 (unless specified otherwise), pre-treated with GFX (2 mM)
for 30 minutes or MK571 (1 mM) and stimulated for 15 minutes
for the phosphorylation of Erk and CREB or 1 h for the
expression of c-fos or 6 h for the measurement of cytokines. The
concentration of MIP1b (Endogen) was measured with ELISAs
according to the manufacturer’s protocol [22]. Transfection of
isoform specific siRNA smart pool constructs from Dharmocon
(10 nM) were carried out using Silentfect transfection reagent
(Biorad) for 48 h according to the manufacturer’s protocol.
Cell Lysates and Western Blotting
After stimulation with the respective agonists, LAD2 cells
(0.56106) were lysed with lysis buffer (BD Bioscience) supple-
mented with protease inhibitor cocktail (Roche) and phosphatase
inhibitor cocktail (pierce). Immunoblotting was performed as
described previously [35]. Briefly, lysates were subjected to 4–12%
SDS-PAGE and transferred to PVDF membrane. Membranes
were incubated with respective primary Phospho- and total
antibodies diluted in 1x TBS, 5% dry milk, 0.1% Tween-20
(1:1000) overnight at 4uC on shaker, and then with secondary
antibody (peroxidase-conjugated anti-rabbit or anti-mouse). West-
ern blot was incubated with ECL and the bands were visualized
using imager (Protein Simple) and quantified using Image J (NIH).
Statistics
Data are expressed as mean 6 SD from at least three
experiments except where otherwise indicated. Data were
converted to a percentage of control for each experiment where
indicated. Significance was determined using Student’s t test as
well as one-way ANOVA followed by Tukey post-hoc analysis.
Results
Cys-LT-mediated Calcium Flux in Mast Cells is Negatively
Regulated by PKC
We have reported earlier that cys-LTs, especially LTD4,
potently induces calcium flux in primary hMCs [21] and also in
LAD2 cells [22]. This signal was sensitive to inhibition by MK571,
implying a requirement for CysLT1R or a CysLT1R-like GPCR in
this signaling event. CysLT1R undergoes ligand-induced desensi-
tization and internalization in heterologous cell systems and these
processes are uniquely dependent on PKC [31]. Based on these
observations, we sought to determine if PKCs have a role in
controlling cys-LT-dependent calcium flux in MCs. Both hMCs
and LAD2 cells were pre-treated with GF109203X (GFX), a
global PKC inhibitor, and its effect on LTD4 or LTE4 stimulation
was evaluated. In the absence of GFX, LTD4 (500 nM) potently
stimulated calcium flux in both cell types, but LTE4 (500 nM) only
caused minimal calcium flux. However, GFX treatment markedly
potentiated LTD4 and LTE4-mediated calcium fluxes in both cell
types (Fig. 1 A, B). Importantly, a specific antagonist of CysLT1R,
MK-571, completely abolished both LTD4 and LTE4-mediated
calcium fluxes in the presence of GFX (Fig. 1C). These
observations suggest that the strength of calcium signaling through
CysLT1R is negatively regulated by PKCs, probably through the
desensitization of the receptors [31,36].
Cysteinyl Leukotriene Signaling in Mast Cells
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PKCs are Required for cys-LT-mediated Phosphorylation
and Expression of c-fos
In rat basophilic leukemia (RBL) cells, Ng et al., demonstrated
that disrupting CysLT1R desensitization by PKC inhibitors can
lead to enhanced LTC4-induced calcium influx, but prevents up-
regulation of c-fos expression through the CRAC channels. Along
these lines, we first checked if stimulation of MCs with LTD4 and
LTE4 induced c-fos expression (Fig. 2). We found that both LTD4
and LTE4 induced robust activation of c-fos at the transcript level
as well as at the protein level. Surprisingly, the induction of c-fos
transcript was maximum at 30 minutes, while the protein
induction was as early as 30 minutes with peak expression at 1 h
and then slowly began to decline after stimulation with either
LTD4 or LTE4 (Fig. 2A, B). To determine the potency of cys-LTs
to induce the expression of c-fos, we treated LAD2 cells with
various concentrations of LTD4 and LTE4 and analyzed
phosphorylation and induction of c-fos (Fig. 2C). LTD4 caused
c-fos induction at doses as low as 1 nM while LTE4 evoked similar
response at relatively higher concentrations (100 nM and
500 nM). On average, we found that 500 nM concentration of
cys-LTs evoked the best response of all the experiments performed
and hence we stimulated cells with 500 nM of cys-LTs in all the
concurrent experiments. Also, we observed that the pattern of
phosphorylation as well as expression of c-fos were similar with
both LTD4 and LTE4, suggesting that cys-LTs not only induced
the expression of c-fos but also activated c-fos. We then asked if
cys-LT-induced c-fos expression and activation are sensitive to
PKC inhibition and are mediated through cysLT1R. Both LTD4
and LTE4-induced c-fos activation as well as expression was
inhibited by GFX as well as MK571 (Fig. 2D). These results
suggest that though PKCs negatively regulate cys-LT-mediated
calcium flux, but are required for cys-LT-mediated c-fos
phosphorylation/expression.
Figure 1. Effect of PKC inhibition on calcium signaling by LTD4 and LTE4 in LAD2 cells. Calcium transients from hMC (A) and LAD2 cells (B)
with cys-LTs (500 nM) in presence or absence of PKC inhibitor, GFX (2 mM) (C) Quantitative analysis of calcium influx from A and B and the effect of
MK571 (1 mM) on the enhanced calcium flux with GFX pre-treatment. The data shown are6SD of three experiments. The significance was tested
using Student’s t-test as well as one-way ANOVA followed by Tukey post-hoc analysis. P,0.05. NS = non-significant.
doi:10.1371/journal.pone.0071536.g001
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MIP1b Generation by cys-LTs is Positively Regulated by
PKCs
Next, we investigated the effect of PKC inhibition on other cys-
LT-induced MC functions. We have shown earlier that cys-LTs
are capable of potently activating inflammatory chemokine,
MIP1b in MCs [22]. Hence, we asked if PKCs play a role in
cys-LT-induced inflammatory responses such as MIP1b produc-
tion in MCs. To determine this, LAD2 cells were pre-treated with
GFX with or without cys-LT stimulation and MIP1b was
measured in the supernatants. As reported earlier [22] and shown
in Fig. 3, both LTD4 and LTE4 potently induced MIP1b
generation. Importantly, unlike calcium flux, MIP1b induction
by both the agonists was significantly blocked by PKC inhibition
with GFX (Fig. 3). These findings suggest the PKCs differentially
regulate cys-LT-induced calcium influx and gene expression in
MCs, possibly via activation of distinct isoforms of PKCs.
PKCs do not Effect cys-LT-activated ERK, or CREB
Pathways
We have shown earlier that cys-LTs activate ERK and CREB
[22] and we sought to investigate if all cys-LT-induced effects are
mediated through PKCs. To our surprise, PKC inhibition by
GFX had no significant effect on the phosphorylation or the
expression of ERK and CREB by cys-LTs (Fig. 4). These results
suggest that cys-LTs have potential to modulate MC function,
both dependent as well as independent of PKCs.
Figure 2. LTD4 and LTE4-induced phosphorylation and expression of c-fos in LAD2 cells and the effect of PKC inhibition. Relative
levels of c-fos transcript (A) upon treatment with 500 nM of LTD4 and LTE4, c-fos phosphorylation and expression with LTD4 or LTE4 (500 nM) for
indicated period (B), Dose response (C), Pre-treated with GFX (2 mM) or MK571 (1 mM) (D), stimulated with 500 nM of cys-LTs and analyzed by western
blotting. Blots were stripped and blotted for GAPDH. The data shown are representative of three separate experiments.
doi:10.1371/journal.pone.0071536.g002
Figure 3. Involvement of PKC in LTD4 and LTE4-induced MIP1b
secretion in LAD2 cells. LAD2 cells were stimulated with 500 nM of
LTD4 or LTE4 for 6 h in presence or absence of GFX (2 mM). The
generation of MIP1b was analyzed from the culture supernatant using
MIP1b-specific ELISA. Data shown are6SD of three independent
experiments. ** P,0.001. NS = non-significant.
doi:10.1371/journal.pone.0071536.g003
Cysteinyl Leukotriene Signaling in Mast Cells
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e71536
PKC Profile in MCs and Identification of cys-LT-responsive
PKC Isoforms
To determine which of the PKC isoforms mediate cys-LT
signaling responses, we first characterized the expression of
different isoforms of PKCs in MCs including classical PKCs (a,
bI, bII, c), novel PKCs (d, e, g, h), and atypical PKCs (f, i/l, m)
by Western blotting. We found that MCs express PKC a, bII, c, d,
e, h and f isoforms (Fig. 5A) and not bI, g, i/l, m (data not
shown). We next asked which of the expressed PKC isoforms are
activated by cys-LTs. Cys-LT responsive PKC isoforms were
determined by analyzing the phosphorylation of individual PKC
isoforms in response to cys-LTs using phospho-specific antibodies.
We found that PKCa and PKCe are phosphorylated by both
LTD4 and LTE4 in a time dependent manner (Fig. 5B, C), but not
PKC bII, c, d, h and f isoforms (data not shown). Phosphorylation
of both PKCa and PKCe in response to cys-LTs was rapid and
transient reaching a peak at 15 minutes and started to decline after
30 minutes. The peak LTE4-induced phosphorylation of PKCe,
but not of PKCa was more gradual than that induced by LTD4.
The small inhibition in the phosphorylation of PKCe that we
observed at 10 minutes compared to 5 minutes in response to
LTE4 is not statistically significant.
PKCa Negatively Regulates cys-LT Mediated Calcium Flux
While PKCe is Essential for MIP1b Generation by cys-LTs
After determining that LTD4 and LTE4 both activated PKCa
and PKCe in MCs, we investigated the specific roles of PKCa and
PKCe in cys-LT-mediated calcium flux, c-fos expression and
MIP1b production (Fig. 6). To determine this, we first knocked
down PKCa and PKCe isoforms in LAD2 cells by transfecting
isoform specific siRNAs (10 nM) against PKCa and PKCe. As a
control, we transfected cells with a non-specific siRNA pool.
Transfection of MCs with PKCa and PKCe siRNAs significantly
down regulated PKCa and PKCe expression (40.064.3% and
41.569.2% down regulation), respectively (Fig. 6A). Down
regulation of PKCa with PKCa siRNA did not have any
significant effect on the expression of PKCe and vice versa (data
not shown). We then assessed cys-LT mediated calcium influx, c-
fos phosphorylation, expression and MIP1b generation in these
cells. Calcium measurements revealed that knock down of PKCa
induced a significant two fold increase in LTD4-induced peak
calcium influx in MCs (Fig. 6B, C). We did not detect any change
in calcium flux induced by LTD4 in PKCe knocked-down MCs
suggesting that PKCa is the key isoform involved in the negative
regulation of cys-LT induced calcium flux. On the other hand,
knockdown of PKCe attenuated both LTD4 and LTE4-induced c-
fos expression (Fig. 6D, E) and phosphorylation (data not shown).
Knock down of PKCe also attenuated cys-LT-induced MIP1b
production in MCs (53% and 55% respectively) (Fig. 6F).
Transfection with control siRNAs did not affect LTD4 and
LTE4-induced c-fos expression or MIP1b generation. Although
PKCa knock down marginally inhibited MIP1b generation, this
signal is not significantly different from control siRNA.
Figure 4. Phosphorylation of Erk and CREB by LAD2 cells in response to LTD4 and LTE4 and the role of PKC in mediating these
effects. (A) phosphorylation as well as total expression of Erk and CREB proteins by Western blotting in cell lysates of LAD2 cells pre-treated with GFX
(2 mM) and stimulated with 500 nM of LTD4 and LTE4 respectively for 30 minutes (B) Quantitative analysis. The shown data represents6SD of three
separate experiments. *P,0.05. NS =non-significant.
doi:10.1371/journal.pone.0071536.g004
Cysteinyl Leukotriene Signaling in Mast Cells
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Discussion
In the present study, we demonstrate that cys-LTs activate two
isoforms of protein kinases, PKCa and PKCe and that these two
isoforms differentially regulate cys-LT-mediated MC function.
PKCe is essential for cys-LT-mediated c-fos expression and
MIP1b generation, while PKCa negatively regulates cys-LT-
induced calcium flux (schematic, Fig. 7). Surprisingly, PKCs
appear to be dispensable for expression and activation of ERK and
CREB.
MCs are relevant cellular effectors of asthma and other allergic
diseases, and cys-LTs are pertinent mediators of the same
processes [37]. The mechanisms that control cys-LT-dependent
biological responses are of considerable pathobiologic and clinical
interest in both allergic and non-allergic disease [38]. We have
previously demonstrated that cys-LTs induce robust calcium flux
in hMCs [21,23] and LAD2 cells via CysLT1R (based on
pharmacologic interference using selective antagonists) [22]. We
have shown earlier that MK571 specifically blocks calcium flux
and Erk phosphorylation in CHO cells expressing CysLT1R, but
not CysLT2R suggesting its specificity [22]. MK571 is also
reported to have inhibitory activity against MRP1 [39]. Further, it
was shown that MK571 treatment increased intracellular LTC4
concentration in eosinophils and modulate IL-4 levels from
preformed vesicles via a putative intracellular CysLT receptor
[40]. However, cys-LT-induced inflammatory mediator produc-
tion in MCs require de novo transcriptional and translational
mechanisms and no such putative intracellular CysLTR has been
identified. Therefore, we believe that the observed inhibitory
effects of MK571 are mostly directed at CysLT1 receptor on the
plasma membrane. In the current study, we elucidate that
pharmacological inhibition of PKCs followed by stimulation of
cells with cys-LTs resulted in significant augmentation of calcium
flux in MCs. This finding is consistent with desensitization of
CysLT1R by PKCs reported in other cell systems. Crooke and
colleagues observed that LTD4 activates PKC, and the same
research team [29,41] noted that inhibitors of PKC increased the
mobilization of Ca2+ induced by LTD4 in the leukemic cell line
RBL-1 using pharmacological activators and inhibitors. Winkler
et al. [30] have reported that the broad PKC inhibitor
staurosporine potentiated the LTD4-induced Ca
2+ signal in
differentiated U-937 cells. In COS-1 cells overexpressing
CysLT1R, pharmacological inhibition of PKC activity was shown
to enhance calcium mobilization stimulated by LTD4 [31].
However the exact molecular mechanism(s) underlying this
process are not well known.
Enhanced receptor activation is usually translated into increased
receptor function. Relief of PKC-mediated desensitization of
endogenous CysLT1R augments multiple LTD4-stimulated cellu-
lar functions, with associated increases in intracellular signaling
events [42]. However, while our data indicate that PKC inhibition
augmented cys-LT-induced calcium signaling, we also found that
it suppressed cys-LT-induced c-fos expression and chemokine
secretion. Activation of c-fos by LTD4 has been reported
previously in HEK cells expressing CysLT1R [43]. Recently, Ng
et al., reported that LTC4-mediated CysLT1R is desensitized by
PKC-dependent phosphorylation and that prevention of this
signaling by PKC inhibition led to loss of calcium-dependent gene
expression, despite potentiation of Ca2+ release [36]. This signal
was proposed to delay the activation of CRAC channels resulting
in the decreased c-fos expression. In the present study using LAD2
cells, we observed that both LTD4 and LTE4 significantly
increased the expression of c-fos, consistent with the earlier study
Figure 5. Identification of possible PKC isoform(s) activated by LTD4 and LTE4 in LAD2 cells. (A) Expression of PKC isoforms and GAPDH
(B) phosphorylation of PKCa and PKCe stimulated with 500 nM of LTD4 or LTE4 for the indicated times (C) Quantitative analysis of relative phospho-
PKC levels in LAD2 cells. Data shown are6SD of three separate experiments.
doi:10.1371/journal.pone.0071536.g005
Cysteinyl Leukotriene Signaling in Mast Cells
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[36]. Our data demonstrate that LTD4 and LTE4 also induce c-fos
phosphorylation. This increase in phosphorylation and expression
of c-fos is mediated through an MK-571 sensitive CysLTR and
PKC. Since cys-LTs activate both Erk and CREB [22], we
investigated if PKC inhibition altered cys-LT-mediated phosphor-
ylation of these signaling molecules. Although cys-LTs robustly
enhanced phosphorylation of Erk and CREB, inhibition of PKCs
surprisingly had no effect on this signal. These findings suggest that
modulation of PKC activity may couple CysLTR signaling to
distinct signaling pathways. It is also possible that at least some of
the PKC-independent signaling events may occur through
receptors other than CysLT1R.
Despite the fact that cys-LT-mediated calcium signaling was
enhanced by global PKC inhibition (Fig. 1), c-fos expression and
MIP1b generation was substantially suppressed. While this finding
could reflect a requirement for CysLT1R receptor desensitization
to facilitate gene induction as suggested by the Ng et al., it also
suggested that cys-LTs activate more than one PKC isoform in
MCs. Indeed, we found that MCs express PKC a, bII, c, d, e, h
and f isoforms but only PKCa and PKCe were phosphorylated in
response to cys-LTs. Notably, we found that PKCa knockdown
significantly augments calcium flux, but has little effect on cys-LT-
induced c-fos and MIP1b production. However, knockdown of
Figure 6. Effect of siRNA-mediated knockdown of PKCa and PKCe on cys-LT-mediated calcium, c-fos and MIP1b generation by LAD2
cells. PKCa and PKCe isoforms were Knocked down using specific siRNAs against PKCa and PKCe (10 nM). Non-specific (NS) siRNA was used as a
control. The siRNA treated cells were analyzed for (A) the expression of PKCa, PKCe and GAPDH, (B, C) LTD4 (500 nM)-induced calcium influx, and
quantitative analysis, (D, E) cys-LT-induced c-fos expression, (F) MIP1b production. Cells were treated with 500 nM of LTD4 and LTE4 for 5 minutes
(calcium flux), 1 h (c-fos expression) and 6 h (MIP1b). Data shown are6SD of three separate experiments. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0071536.g006
Figure 7. A model depicting PKC regulated cys-LT signaling in
MCs. Hypothetical mechanism(s) depicting cys-LT-mediated signaling
in MCs by PKCs. CysLT1R activation by LTD4 or LTE4 activates PKCa and
PKCe. PKCa desensitize CysLT1R by phosphorylating the receptor and
negatively regulating the calcium flux. On the other hand, PKCe
activation by CysLT1R activates c-fos expression, MIP1b production. Cys-
LTs also activate Erk and CREB independent of PKCs.
doi:10.1371/journal.pone.0071536.g007
Cysteinyl Leukotriene Signaling in Mast Cells
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PKCe significantly attenuated cys-LT-induced c-fos phosphoryla-
tion, expression and MIP1b production without altering calcium
flux. Activation of PKCe by cys-LTs has been showed in other
systems [17,32,44] as well. Interestingly, PKCe was shown to be
essential for LTD4-induced calcium signal in intestinal epithelial
cells, suggesting that coupling of cys-LTs to signaling events is
regulated in a cell type-specific manner. In conclusion, our study
identifies specific isoforms of PKCs, PKCa and PKCe that are
activated by cys-LTs and differentially regulate distinct MC
functions, critical for the progression and pathology of asthma.
Understanding the signaling and players involved in CysLTR
regulation can be useful in identifying better therapeutic targets for
inflammatory asthma and allergic diseases.
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